Research Type: Extramural
Dr Mithraprabhu and her team aims to overcome the challenges caused by the genetic complexity of multiple myeloma by using DNA obtained from the blood instead of a single-site bone marrow biopsy.
The team has developed a methodology to map the fibrotic tumour landscape, through real-time imaging of (i) the proximity of cancer cells to the host blood supply, (ii) their location with regards to the tumour invasive borders and (iii) the surrounding tissue compartment.
Associate Professor MacKenzie and her team will define specific drug targets and develop diagnostic methods for therapeutic application in cancers that relay on a specific telomere maintenance mechanism referred to as Alternative Lengthening of Telomeres (ALT).
Dr Jenny Wang and her team have discovered a key self-renewal pathway essential for the survival of leukaemia-initiating cells.
Dr Latham’s team is pursuing the preclinical assessment and development of a novel class of drugs that aim to prevent cancer relapse by inhibiting the growth of cells that have already metastasised.
Dr Pidsley’s research will lead to the development of a novel sensitive epigenetic test, to accurately determine tumour risk, particularly for tumours that are inaccurately classified using current clinical tools.
Dr Beatriz Perez San Juan’s research is focussed on developing new targeted treatments for triple negative breast cancer that overcome the challenge of chemotherapy failure.
Professor Holst and Dr Centenera’s teams aim to develop a new drug treatment strategy to overcome resistance to hormone therapy in prostate cancer.
Associate Professor Thomas Cox and his team have identified a molecule in the lung tissue matrix called ‘Collagen IV’, which helps to control the behaviour of lung cancer cells.
Professor Murray Norris and his team will study RUNX1T1, building a detailed understanding of its role in maintaining normal function of embryonic stem cells, to develop a new way to treat childhood cancers.